title: Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer.
abstract: One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.
authors.affiliation: The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.
authors.forename: Xue-Hui
authors.initials: XH
authors.lastname: Chen
authors.forename: Zhi-Qiang
authors.initials: ZQ
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Peng
authors.forename: Su-Mei
authors.initials: SM
authors.lastname: Jin
authors.forename: Hui-Qing
authors.initials: HQ
authors.lastname: Fu
authors.forename: Tie-Chui
authors.initials: TC
authors.lastname: Zhu
authors.forename: Xiao-Gang
authors.initials: XG
authors.lastname: Weng
keywords: IGF; IGF-1R; apoptosis; hepatocellular carcinoma